High-Grade Glioma - Pipeline Review, H1 2017 - Product Image

High-Grade Glioma - Pipeline Review, H1 2017

  • ID: 4318739
  • Report
  • 253 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AngioChem Inc
  • Athenex Inc
  • BTG Plc
  • Ipsen SA
  • Ono Pharmaceutical Co Ltd
  • Targepeutics Inc
  • MORE
High-Grade Glioma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AngioChem Inc
  • Athenex Inc
  • BTG Plc
  • Ipsen SA
  • Ono Pharmaceutical Co Ltd
  • Targepeutics Inc
  • MORE
  1. Introduction
  2. High-Grade Glioma - Overview
  3. High-Grade Glioma - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. High-Grade Glioma - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. High-Grade Glioma - Companies Involved in Therapeutics Development
  15. Advenchen Laboratories LLC
  16. AngioChem Inc
  17. Arog Pharmaceuticals Inc
  18. Astellas Pharma Inc
  19. Athenex Inc
  20. Bayer AG
  21. Boehringer Ingelheim GmbH
  22. Bristol-Myers Squibb Company
  23. BTG Plc
  24. Cavion LLC
  25. CBT Pharmaceuticals Inc
  26. Concordia International Corp
  27. DelMar Pharmaceuticals Inc
  28. Ipsen SA
  29. Millennium Pharmaceuticals Inc
  30. Nektar Therapeutics
  31. Novartis AG
  32. Ono Pharmaceutical Co Ltd
  33. Sanofi
  34. Sorrento Therapeutics Inc
  35. Sumitomo Dainippon Pharma Co Ltd
  36. Targepeutics Inc
  37. Tocagen Inc
  38. ZIOPHARM Oncology Inc
  39. High-Grade Glioma - Drug Profiles
  40. AdRTSIL-12 - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. afatinib dimaleate - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. alisertib - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. apatinib - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. bendamustine hydrochloride - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. BMX-001 - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. cabazitaxel - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. CBT-101 - Drug Profile
  69. Product Description
  70. Mechanism Of Action
  71. R&D Progress
  72. Cellular Immunotherapy for Gliomas - Drug Profile
  73. Product Description
  74. Mechanism Of Action
  75. R&D Progress
  76. Cellular Immunotherapy for High-Grade Glioma - Drug Profile
  77. Product Description
  78. Mechanism Of Action
  79. R&D Progress
  80. Cellular Immunotherapy for Oncology - Drug Profile
  81. Product Description
  82. Mechanism Of Action
  83. R&D Progress
  84. crenolanib besylate - Drug Profile
  85. Product Description
  86. Mechanism Of Action
  87. R&D Progress
  88. CYT-107 - Drug Profile
  89. Product Description
  90. Mechanism Of Action
  91. R&D Progress
  92. dabrafenib mesylate - Drug Profile
  93. Product Description
  94. Mechanism Of Action
  95. R&D Progress
  96. dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
  97. Product Description
  98. Mechanism Of Action
  99. R&D Progress
  100. dianhydrogalactitol - Drug Profile
  101. Product Description
  102. Mechanism Of Action
  103. R&D Progress
  104. DSP-7888 - Drug Profile
  105. Product Description
  106. Mechanism Of Action
  107. R&D Progress
  108. etirinotecan pegol - Drug Profile
  109. Product Description
  110. Mechanism Of Action
  111. R&D Progress
  112. flucytosine + TBio-01 - Drug Profile
  113. Product Description
  114. Mechanism Of Action
  115. R&D Progress
  116. flucytosine ER + vocimagene amiretrorepvec - Drug Profile
  117. Product Description
  118. Mechanism Of Action
  119. R&D Progress
  120. GB-13 - Drug Profile
  121. Product Description
  122. Mechanism Of Action
  123. R&D Progress
  124. HSV-1716 - Drug Profile
  125. Product Description
  126. Mechanism Of Action
  127. R&D Progress
  128. ipilimumab + nivolumab - Drug Profile
  129. Product Description
  130. Mechanism Of Action
  131. R&D Progress
  132. irinotecan hydrochloride - Drug Profile
  133. Product Description
  134. Mechanism Of Action
  135. R&D Progress
  136. irinotecan hydrochloride + TBio-02 - Drug Profile
  137. Product Description
  138. Mechanism Of Action
  139. R&D Progress
  140. irinotecan hydrochloride CR - Drug Profile
  141. Product Description
  142. Mechanism Of Action
  143. R&D Progress
  144. KX-02 - Drug Profile
  145. Product Description
  146. Mechanism Of Action
  147. R&D Progress
  148. mibefradil dihydrochloride - Drug Profile
  149. Product Description
  150. Mechanism Of Action
  151. R&D Progress
  152. nivolumab - Drug Profile
  153. R&D Progress
  154. Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile
  155. Product Description
  156. Mechanism Of Action
  157. R&D Progress
  158. paclitaxel trevatide - Drug Profile
  159. Product Description
  160. Mechanism Of Action
  161. R&D Progress
  162. porfimer sodium - Drug Profile
  163. Product Description
  164. Mechanism Of Action
  165. R&D Progress
  166. RRX-001 - Drug Profile
  167. Product Description
  168. Mechanism Of Action
  169. R&D Progress
  170. sorafenib tosylate - Drug Profile
  171. Product Description
  172. Mechanism Of Action
  173. R&D Progress
  174. High-Grade Glioma - Dormant Projects
  175. High-Grade Glioma - Discontinued Products
  176. High-Grade Glioma - Product Development Milestones
  177. Featured News & Press Releases
  178. May 11, 2017: Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting
  179. Mar 16, 2017: Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia
  180. Feb 23, 2017: Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma
  181. Nov 21, 2016: Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings
  182. Nov 10, 2016: Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings
  183. Oct 05, 2016: Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy
  184. Sep 30, 2016: Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings
  185. May 13, 2016: Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings
  186. May 03, 2016: Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting
  187. Apr 13, 2016: Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences
  188. Nov 23, 2015: Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
  189. Nov 18, 2015: Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
  190. Jul 09, 2015: FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
  191. Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
  192. May 28, 2015: Cavion to Present Clinical Trial Data at ASCO
  193. Appendix
  194. Methodology
  195. Coverage
  196. Secondary Research
  197. Primary Research
  198. Expert Panel Validation
  199. Contact Us
  200. Disclaimer
List of Tables
  1. Number of Products under Development for High-Grade Glioma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Universities/Institutes, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Products under Development by Universities/Institutes, H1
  8. Number of Products by Stage and Target, H1
  9. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  10. Number of Products by Stage and Mechanism of Action, H1
  11. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  12. Number of Products by Stage and Route of Administration, H1
  13. Number of Products by Stage and Molecule Type, H1
  14. High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H1
  15. High-Grade Glioma - Pipeline by AngioChem Inc, H1
  16. High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H1
  17. High-Grade Glioma - Pipeline by Astellas Pharma Inc, H1
  18. High-Grade Glioma - Pipeline by Athenex Inc, H1
  19. High-Grade Glioma - Pipeline by Bayer AG, H1
  20. High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1
  21. High-Grade Glioma - Pipeline by Bristol-Myers Squibb Company, H1
  22. High-Grade Glioma - Pipeline by BTG Plc, H1
  23. High-Grade Glioma - Pipeline by Cavion LLC, H1
  24. High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H1
  25. High-Grade Glioma - Pipeline by Concordia International Corp, H1
  26. High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H1
  27. High-Grade Glioma - Pipeline by Ipsen SA, H1
  28. High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H1
  29. High-Grade Glioma - Pipeline by Nektar Therapeutics, H1
  30. High-Grade Glioma - Pipeline by Novartis AG, H1
  31. High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1
  32. High-Grade Glioma - Pipeline by Sanofi, H1
  33. High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H1
  34. High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1
  35. High-Grade Glioma - Pipeline by Targepeutics Inc, H1
  36. High-Grade Glioma - Pipeline by Tocagen Inc, H1
  37. High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H1
  38. High-Grade Glioma - Dormant Projects, H1
  39. High-Grade Glioma - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for High-Grade Glioma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advenchen Laboratories LLC
  • AngioChem Inc
  • Arog Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Athenex Inc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • BTG Plc
  • Cavion LLC
  • CBT Pharmaceuticals Inc
  • Concordia International Corp
  • DelMar Pharmaceuticals Inc
  • Ipsen SA
  • Millennium Pharmaceuticals Inc
  • Nektar Therapeutics
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Sanofi
  • Sorrento Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Targepeutics Inc
  • Tocagen Inc
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll